Neuroplast
France - MontpellierBiotechnology
Focus: Neuroplast is a French biotech company focused on autologous stem cell therapies for cell therapy applications, specifically targeting spinal cord injuries and cerebral ischemia. The company is publicly listed but remains early-stage with a small pipeline in Phase 1–2/3 development.
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Neuroplast
AI assessmentNot HiringNo open roles listed right now. Follow Neuroplast to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Neuroplast's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia
Delayed Cerebral IschemiaBone Marrow Collection in Healthy Volunteers (iCell)
Spinal Cord InjuryHelp build intelligence for Neuroplast
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.